Upexi (UPXI) Competitors $7.26 +2.06 (+39.62%) Closing price 04:00 PM EasternExtended Trading$7.22 -0.04 (-0.62%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPXI vs. PGEN, SIGA, ATYR, ORKA, CAPR, CGEM, MREO, KMDA, RAPP, and RGNXShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Precigen (PGEN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Oruka Therapeutics (ORKA), Capricor Therapeutics (CAPR), Cullinan Therapeutics (CGEM), Mereo BioPharma Group (MREO), Kamada (KMDA), Rapport Therapeutics (RAPP), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Its Competitors Precigen Siga Technologies aTyr Pharma Oruka Therapeutics Capricor Therapeutics Cullinan Therapeutics Mereo BioPharma Group Kamada Rapport Therapeutics REGENXBIO Upexi (NASDAQ:UPXI) and Precigen (NASDAQ:PGEN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Do institutionals and insiders hold more shares of UPXI or PGEN? 5.7% of Upexi shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 31.6% of Upexi shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is UPXI or PGEN more profitable? Upexi has a net margin of -135.86% compared to Precigen's net margin of -3,728.87%. Precigen's return on equity of -279.20% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Upexi-135.86% -535.19% -122.94% Precigen -3,728.87%-279.20%-79.74% Do analysts recommend UPXI or PGEN? Upexi presently has a consensus target price of $16.00, suggesting a potential upside of 120.39%. Precigen has a consensus target price of $6.00, suggesting a potential upside of 226.09%. Given Precigen's higher possible upside, analysts plainly believe Precigen is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Precigen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to UPXI or PGEN? In the previous week, Upexi and Upexi both had 7 articles in the media. Precigen's average media sentiment score of 1.18 beat Upexi's score of 0.46 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, UPXI or PGEN? Upexi has a beta of -0.58, suggesting that its share price is 158% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Which has preferable valuation and earnings, UPXI or PGEN? Upexi has higher revenue and earnings than Precigen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpexi$26M10.59-$23.66MN/AN/APrecigen$3.92M138.55-$126.24M-$0.56-3.29 SummaryPrecigen beats Upexi on 9 of the 12 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$275.30M$2.46B$15.04B$9.31BDividend YieldN/A1.45%2.73%4.03%P/E RatioN/A31.0228.1719.73Price / Sales10.5935.46570.23174.40Price / CashN/A43.7126.3357.96Price / Book1.166.086.445.67Net Income-$23.66M$33.22M$196.70M$257.79M7 Day Performance74.10%0.89%0.59%0.54%1 Month Performance-26.22%7.47%5.53%8.86%1 Year Performance-13.57%33.69%22.04%14.22% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi2.2218 of 5 stars$7.26+39.6%$16.00+120.4%-39.5%$275.30M$26M0.00130Gap UpHigh Trading VolumePGENPrecigen4.0427 of 5 stars$1.59-1.9%$6.00+277.4%+12.5%$478.19M$4.20M-2.84190News CoveragePositive NewsAnalyst RevisionSIGASiga Technologies2.2222 of 5 stars$6.73+0.6%N/A-26.6%$477.94M$138.72M10.0440News CoverageATYRaTyr Pharma2.0541 of 5 stars$5.30-0.2%$20.20+281.1%+219.0%$472.61M$230K-6.5453Gap DownHigh Trading VolumeORKAOruka Therapeutics2.929 of 5 stars$13.29+5.5%$40.38+203.8%N/A$471.75MN/A-2.95N/ANews CoveragePositive NewsCAPRCapricor Therapeutics2.5329 of 5 stars$9.90-3.4%$32.22+225.5%+54.1%$468.19M$22.27M-6.97101Analyst ForecastAnalyst RevisionCGEMCullinan Therapeutics1.7321 of 5 stars$7.42-5.0%$30.00+304.3%-55.1%$460.90MN/A-2.5530News CoverageMREOMereo BioPharma Group1.5689 of 5 stars$2.92+1.7%$7.60+160.3%-58.8%$456.33M$10M-41.7140High Trading VolumeKMDAKamada4.3038 of 5 stars$7.71-2.2%$13.00+68.6%+30.8%$453.14M$167.24M26.59360RAPPRapport Therapeutics1.6337 of 5 stars$12.04flat$28.00+132.6%-42.5%$439.43MN/A-3.49N/ANews CoverageRGNXREGENXBIO3.9991 of 5 stars$8.43-3.5%$31.63+275.1%-36.0%$438.40M$83.33M-2.71370 Related Companies and Tools Related Companies PGEN Alternatives SIGA Alternatives ATYR Alternatives ORKA Alternatives CAPR Alternatives CGEM Alternatives MREO Alternatives KMDA Alternatives RAPP Alternatives RGNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPXI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
